The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CML/MPN 2025 | Challenges with diagnosing and treating patients in the pre-fibrotic phase of primary myelofibrosis
Martin Griesshammer, MD, Johannes Wesling Medical Center, Minden, Germany, briefly comments on the challenges of diagnosing and treating patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF), highlighting the need for precise use of the term and individualized treatment approaches based on the patient’s clinical presentation. Prof. Griesshammer notes that the lack of studies and data on this patient population complicates diagnosis and treatment decisions. This interview took place at the European School of Haematology (ESH) 4th How to Diagnose and Treat: CML/MPN meeting in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Prefibrotic myelofibrosis is a difficult disease because, as it says within the name, it’s prefibrotic and it’s fibrotic. So what is it really? And we have this term which is clearly defined by the WHO, but we as clinicians advising patients have many problems because there is a lack of studies especially for this patient population. So we have the name but we have not as much experience how and when to treat these patients...
Prefibrotic myelofibrosis is a difficult disease because, as it says within the name, it’s prefibrotic and it’s fibrotic. So what is it really? And we have this term which is clearly defined by the WHO, but we as clinicians advising patients have many problems because there is a lack of studies especially for this patient population. So we have the name but we have not as much experience how and when to treat these patients.
So this position paper deals with the question how this may be because still data are lacking. So what we are suggesting is to use this term very precisely and to advise these patients according to their clinical picture. Some patients are more ET-like, essential thrombocythemia-like, others are more fibrosis-like. And this is roundabout what we recommend how to treat this patient. But we especially tip on the problem that there is a lack of data in prefibrotic myelofibrosis and you have to be very careful to use this term and to explain the patient apart from this term how their individual clinical situation is.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
